Celiac disease in Iranian irritable bowel syndrome patients; a systematic review and meta-analysis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 2 (2019),
18 March 2019
,
Page 85-97
https://doi.org/10.22037/ghfbb.v12i2.1484
Abstract
Aim: The present study was conducted to evaluate the prevalence, clinical symptoms and pathological findings of celiac disease (CD) in irritable bowel syndrome (IBS) patients in Iran.
Background: Several studies show high prevalence of CD in IBS patients, but the results are contradictory.
Methods: The present study was conducted based on MOOSE protocol and results were reported according to PRISMA guideline. The search was done using international online databases (Scopus, PubMed, Science Direct, Cochrane Library, Embase, and Web of Science), national databases and Google Scholar search engine.
Results: The pooled prevalence of CD in 2,367 Iranian IBS patients was estimated to be 6.13% (95%CI: 4.11-9.05). The prevalence of CD in men and women with IBS was 4.28% (95% CI: 2.45-7.37) and 7.19% (95% CI: 4.51-11.28), respectively. The serological prevalence of anti tTG-IgA (11 studies with 2901 IBS patients) and AGA-IgG (4 studies with 936 IBS patients) was estimated to be 5.35% (95%CI: 3.60-7.89) and 6.35% (95%CI: 2.05-18.03), respectively. The clinical symptoms of CD among IBS patients included predominant diarrhea (47.87% [95%CI: 22.46-74.43]), predominant constipation (17.34% [95%CI: 9.17-30.35]), and alternative diarrhea and constipation (27.84% [95%CI: 11.57-53.23]). According to pathological findings based on marsh classification, the prevalence of CD at stages 1, 2 and 3 were 30.89% (95%CI: 13.25-56.68), 36.56% (95%CI: 21.74-54.45) and 52.87% (95%CI: 14.48-88.13), respectively.
Conclusion: In the present meta-analysis, we observed a high prevalence for CD among Iranian IBS patients, which is higher than global estimates. Examination of all IBS patients in terms of CD seems to be necessary, but cost-effectiveness should be considered.
Keywords: Celiac disease, Irritable bowel syndrome, Meta-Analysis, Iran.
(Please cite as: Azami M, Badfar GH, Abangah GH, Mahmoudi L. Celiac disease in Iranian irritable bowel syndrome patients: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench 2019;12(2):85-97).
- Celiac disease
- Irritable bowel syndrome
- Meta-Analysis
- Iran.
How to Cite
References
Green PHR, Cellier C. Celiac disease. N Engl J Med. Mass Med Soc 2007;357:1731-43.
Ahadi Z, Shafiee G, Razmandeh R, Keshtkar AA, Najafi Sani M, Azemati B, et al. Prevalence of celiac disease among the Iranian population: A systematic review and meta-analysis of observational studies. Turk J Gastroenterol 2016;27:122-8.
Green PH. Themany faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005;128:S74-8.
Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002; 346:180-8.
Green PHR. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005;128:S74-8.
Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principle of internal medicine. 17th edition. New York: Mc Graw-Hill; 2008. p:1899-1903.
Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. J Clin Pathol. BMJ Publish Group Ltd Assoc Clin Pathol 2006;59:1008-1016.
Kapitany A, Toth L, Tumpek J, Sipos E, Woolley N, Partanen J, et al. Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone. Aliment Pharmacol Ther 2006;24:1395-1402.
Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel) 2017;5. pii: E21.
Jahangiri P, Jazi MS, Keshteli AH, Sadeghpour S, Amini E, Adibi P. Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1. Int J Prev Med 2012;3:S1-9.
Khademolhosseini F, Mehrabani D, Nejabat M, Beheshti M, Heydari ST, Mirahmadizadeh A, et al. Irritable bowel syndrome in adults over 35 years in Shiraz, southern Iran: prevalence and associated factors. J Res Med Sci 2011;16:200-6. [In Persian]
Chogle A, Mintjens S, Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann 2014;43(4):e76-82.
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ. Muller-Lissner, functional bowel disorders and functional abdominal pain. Gut 1999;45:1143–7.
Catassi C, Kryszak D, Louis-Jacques O, Duerksen DR, Hill I, Crowe SE, et al. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol 2007;102:1454-60.
Emami MH, Kouhestani S, Gholamrezaei A, Hashemi M, Mahzouni P, Raeisi M, et al. Prevalence of Celiac Disease in Patients with Irritable Bowel Syndrome. Govaresh 2008;13:192-7.
Ahmadi B; Zaherara M. Prevalence of celiac disease in patients with irritable bowel syndrome in Kerman, Iran. J Kerman Univ Med Sci 2015;22:319-27.
Akhondi-Meybodi M, Rabiei A, Salehi S. The prevalence of CD in patients with irritable bowel syndrome with diarrheapredominant feature gastroenterology clinic of Yazd. Yazd Univ Me Sci J 2011;19:637-43. [In Persian]
Jafarihaydarlo A, Mahmoodi AR, Yasemi M, Baziar A, Ehsanbakhsh S, Rashidbeygi M. Frequency of Celiac Disease in Patients with Diarrhea Predominant Irritable Bowel Syndrome Referred to Gastroenterology Clinics in Ilam During 2008 to 2012. J Ilam Univ Med Sci 2013;21:191-18. [In Persian]
Mahmoodi A, Jafarihaydarlo A, Yasemi M, Hemati K, Peyman H. Celiac Disease Prevalence in the Patients with Irritable Bowel Syndrome in the Ilam Province; A Cross Sectional Study from Western Iran. J Clin Diag Res 2014;8:GC01-3.
Mehdi Z, Sakineh E, Mohammad F, Mansour R, Alireza A. Celiac disease: Serologic prevalence in patients with irritable bowel syndrome. J Res Med Sci 2012;17:839-42.
Safari A, Khakzad MR, Fumani A, Mashkat M, Mirsadraee M. Frequency of Antigliadin and Anti-transglutaminase in Patients with Irritable Bowel Syndrome. Med Sci J Islam Azad Univ Mashhad 2008;4:2.3-8. [In Persian]
Bakhshipour A, Nezam S K, Zakeri Z, Gharibi R, Bahari A, Kaykhaei MA. Coeliac disease in irritable bowel syndrome (Rome III) in Southeast Iran. Arab J Gastroenterol 2012;13:24–7.
Houshiyar A, Fouladi N, Amani F,Alimohammadi Asl H, Ghorbani F. Prevalence of celiac disease in patients with irritable bowel syndrome in Ardabil-Iran (2009-10). J Gorgan Univ Med Sc 2013;14:29. [In Persian]
Amiriani T, Besharat S, Roshandel G, Shalizar A. Should we look for celiac disease in irritable bowel syndrome? Oman Med J 2011;26:59-60.
Shahbazkhani B, Forootan M, Merat S, Akbari MR, Nasserimoghadam S, Vahedi H, et al. Coeliac disease presenting with symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:231-5.
Shayesteh AA, Hajiani E, Hashemi SJ, Masjedizadeh A, Latifi SM, Shayesteh M. Prevalence of celiac disease in Iranian patients with irritable bowel syndrome: a cross-sectional study. J Dig Dis 2014;15:12-7.
Azami M, Hafezi Ahmadi MR, Sayehmiri K. Hepatitis B Vaccination Efficacy in Iranian Healthcare Workers: A Meta-Analysis Study. Hepat Mon 2017;17:e37781.
Sayehmiri K, Abangah G, Kalvandi G, Tavan H, Aazami S. Prevalence of peptic ulcer in Iran: Systematic review and meta-analysis methods. J Res Med Sci. 2018;23:8. [In Persian]
Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA Statement. Open Med 2009;3:e123–30.
Cota GF, De Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. Plos Negl Trop Dis 2013;7:e2195.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from: http://handbook.cochrane.org/.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557–60.
Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Inter Med 2009;169:651-8.
Irvine AJ, Chey WD3, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol 2017;112:65-76.
Krigel A, Turner KO, Makharia GK, Green PH, Genta RM, Lebwohl B. Ethnic Variations in Duodenal Villous Atrophy Consistent With Celiac Disease in the United States. Clin Gastroenterol Hepatol 2016;14:1105-11.
Ramakrishna BS, Makharia GK, Chetri K, Dutta S, Mathur P, Ahuja V, et al. Prevalence of Adult Celiac Disease in India: Regional Variations and Associations. Am J Gastroenterol 2016;111:115-23.
Kang JY, Kang AH, Green A, Gwee KA, Ho KY. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther 2013;38:226-45.
Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010;31:73-81.
Ciclitira PJ, King AL, Fraser JS. American Gastroenterological Association AGA technical review on Celiac Sprue. Gastroenterology 2001;120:1526-40.
Mein SM, Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004;19:1199-210.
Spiegel BM, De Rosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004;126:1721-32.
Mohseninejad L, Feenstra T, Van Der Horst HE, Woutersen-Koch H, Buskens E. Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. Eur J Health Econ 2013;14:947-57.
Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005;128:S25–32 .
Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011;140:91–100.
Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. BSG Coeliac Disease Guidelines Development Group; British Society of Gastroenterology. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210-28.
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71–80.
Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122:1140–56.
Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, Morgan A, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20:455–62.
- Abstract Viewed: 166 times
- PDF Downloaded: 114 times